Nurix Therapeutics, Inc.

Equities

NRIX

US67080M1036

Biotechnology & Medical Research

Market Closed - Nasdaq Other stock markets 04:00:00 2024-07-12 pm EDT			5-day change	1st Jan Change
23.82 ^USD	+8.13%		+22.34%	+130.81%

Jul. 12	Needham Adjusts Price Target on Nurix Therapeutics to $29 From $31, Maintains Buy Rating	MT
Jul. 12	RBC Lifts Price Target on Nurix Therapeutics to $27 From $26, Keeps Outperform, Speculative Risk	MT

Nurix Therapeutics, Inc. Reports Earnings Results for the Fourth Quarter and Full Year Ended November 30, 2021

January 27, 2022 at 04:08 pm EST

Nurix Therapeutics, Inc. reported earnings results for the fourth quarter and full year ended November 30, 2021. For the fourth quarter, the company reported net loss was USD 37.7 million compared to USD 19.91 million a year ago. Basic loss per share from continuing operations was USD 0.85 compared to USD 0.51 a year ago.
For the full year, net loss was USD 117.19 million compared to USD 43.24 million a year ago. Basic loss per share from continuing operations was USD 2.73 compared to USD 2.76 a year ago.

Latest news about Nurix Therapeutics, Inc.

Needham Adjusts Price Target on Nurix Therapeutics to $29 From $31, Maintains Buy Rating	Jul. 12	MT
RBC Lifts Price Target on Nurix Therapeutics to $27 From $26, Keeps Outperform, Speculative Risk	Jul. 12	MT
Nurix Therapeutics Q2 Loss Widens Amid Revenue Decline	Jul. 11	MT
Nurix Therapeutics, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended May 31, 2024	Jul. 11	CI
Earnings Flash (NRIX) NURIX THERAPEUTICS Reports Q2 Revenue $12.1M	Jul. 11	MT
Nurix Therapeutics, Inc.(NasdaqGM:NRIX) added to Russell Microcap Growth Index	Jun. 30	CI
Nurix Therapeutics, Inc.(NasdaqGM:NRIX) added to Russell 3000E Growth Index	Jun. 30	CI
Nurix Therapeutics, Inc.(NasdaqGM:NRIX) added to Russell 3000 Growth Index	Jun. 30	CI
Nurix Therapeutics, Inc.(NasdaqGM:NRIX) added to Russell 2000 Growth Index	Jun. 30	CI
Nurix Therapeutics, Inc.(NasdaqGM:NRIX) added to Russell 2500 Growth Index	Jun. 30	CI
Nurix Therapeutics, Inc.(NasdaqGM:NRIX) added to Russell Small Cap Comp Growth Index	Jun. 30	CI
RBC Raises Price Target on Nurix Therapeutics to $26 From $23, Maintains Outperform, Speculative Risk	Jun. 27	MT
Nurix Therapeutics Insider Sold Shares Worth $400,216, According to a Recent SEC Filing	Jun. 20	MT
HC Wainwright Raises Price Target on Nurix Therapeutics to $26 From $19, Maintains Buy Rating	Jun. 18	MT
JPMorgan Adjusts Price Target on Nurix Therapeutics to $31 From $30, Maintains Overweight Rating	Jun. 17	MT
Sector Update: Health Care Stocks Decline Premarket Monday	Jun. 17	MT
Investors Look for Fresh Impetus Ahead of Holiday Break, Stifling US Equity Futures Pre-Bell	Jun. 17	MT
Sector Update: Health Care	Jun. 17	MT
Exchange-Traded Funds, Equity Futures Mixed Pre-Bell Monday Ahead of More Economic Data	Jun. 17	MT
Top Premarket Gainers	Jun. 17	MT
Nurix Therapeutics Says Patients Respond Well to Potential Non-Hodgkin Lymphoma Treatment in Phase 1 Trial	Jun. 17	MT
Transcript : Nurix Therapeutics, Inc. - Special Call	Jun. 16
Nurix Therapeutics Presents Positive Results from Ongoing Clinical Trial of NX-5948 in Patients with Relapsed Refractory Chronic Lymphocytic Leukemia At the European Hematology Association Congress	Jun. 16	CI
Nurix Therapeutics Files Mixed Shelf Registration	Jun. 11	MT
Certain Restricted Stock Units of Nurix Therapeutics, Inc. are subject to a Lock-Up Agreement Ending on 11-JUN-2024.	Jun. 10	CI

Chart Nurix Therapeutics, Inc.

Duration

Period

More charts

Company Profile

Nurix Therapeutics, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on the discovery, development and commercialization of small molecules and antibody therapies based on the modulation of cellular protein levels as a treatment approach for cancer, inflammatory conditions and other diseases. It DELigase is an integrated discovery platform, to identify and advance drug candidates targeting E3 ligases. Its drug candidates include NX-2127, NX-5948 and NX-1607. NX-2127 is an orally bioavailable Brutons tyrosine kinase (BTK) degrader that also degrades cereblon neosubstrates IKZF1 (Ikaros) and IKZF3 (Aiolos) for the treatment of relapsed or refractory B-cell malignancies. NX-5948 is an orally bioavailable BTK degrader for the treatment of relapsed or refractory B-cell malignancies and potentially autoimmune diseases. NX-1607 is an oral clinical-stage small molecule drug candidate that inhibits Casitas B-lineage lymphoma proto-oncogene-B (CBL-B).

Sector

Biotechnology & Medical Research

Calendar

2024-07-15 - UBS Targeted Protein Degradation Day

More about the company

Income Statement Evolution

More financial data

Ratings for Nurix Therapeutics, Inc.

Trading Rating

Investor Rating

ESG Refinitiv

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

23.82 USD

Average target price

28.33 USD

Spread / Average Target

+18.95%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Bio Therapeutic Drugs

	1st Jan change	Capi.
NURIX THERAPEUTICS, INC.	+130.81%	1.53B
VERTEX PHARMACEUTICALS INCORPORATED	+20.12%	126B
REGENERON PHARMACEUTICALS, INC.	+25.25%	119B
ARGENX SE	+25.56%	27.95B
BIONTECH SE	-19.51%	20.5B
GENMAB A/S	-14.36%	17.12B
BEIGENE, LTD.	-15.63%	16.1B
WUXI APPTEC CO., LTD.	-46.67%	14.97B
NEUROCRINE BIOSCIENCES, INC.	+11.89%	14.84B
SAREPTA THERAPEUTICS, INC.	+57.74%	14.38B

Bio Therapeutic Drugs